pioglitazone has been researched along with Cholangiocarcinoma in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the effect and mechanism of ligand pioglitazone (PGZ) activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro." | 7.74 | [Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes]. ( Cao, GQ; Chen, QY; Cheng, NS; Li, M; Wu, LH; Xiong, XZ; Zhang, FQ, 2007) |
| "Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat." | 5.34 | Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. ( Hashizume, K; Hosoda, W; Mori, J; Sato, A; Suzuki, S; Yamazaki, M, 2007) |
| "To explore the effect and mechanism of ligand pioglitazone (PGZ) activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro." | 3.74 | [Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes]. ( Cao, GQ; Chen, QY; Cheng, NS; Li, M; Wu, LH; Xiong, XZ; Zhang, FQ, 2007) |
| "Cholangiocarcinoma is a predominantly fatal cancer, which can be difficult to treat." | 1.34 | Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. ( Hashizume, K; Hosoda, W; Mori, J; Sato, A; Suzuki, S; Yamazaki, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kobuke, T | 1 |
| Tazuma, S | 1 |
| Hyogo, H | 1 |
| Chayama, K | 1 |
| Li, M | 1 |
| Cheng, NS | 1 |
| Xiong, XZ | 1 |
| Wu, LH | 1 |
| Chen, QY | 1 |
| Zhang, FQ | 1 |
| Cao, GQ | 1 |
| Suzuki, S | 1 |
| Mori, J | 1 |
| Yamazaki, M | 1 |
| Sato, A | 1 |
| Hosoda, W | 1 |
| Hashizume, K | 1 |
3 other studies available for pioglitazone and Cholangiocarcinoma
| Article | Year |
|---|---|
A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3; Caspase | 2006 |
[Effect of ligand pioglitazone activating PPAR-gamma on the invasiveness of cholangiocarcinoma cell in vitro and the expression regulation of related genes].
Topics: Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Dose-Response Relationship, Drug; Gene Expressi | 2007 |
Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diabetes Mellitus, Type 2; | 2007 |